TG Therapeutics Raises $60m Following Combo Therapy Success In CLL

 
• By Joseph Haas
  
Winning, victory, success and surviving concept. Green board game pawn stand alone, the white rest fallen. Eliminating competitors. One against the others. Last man standing. Against all odds.
TG Therapeutics' U2 combo topped a comparator regimen for PFS in CLL patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D